Ipsen Pays $575m Upfront For Struggling Pancreatic Drug Onivyde

Ipsen's new CEO David Meek has conducted the French company's biggest ever deal by acquiring Onivyde for pancreatic cancer from Merrimack Pharmaceuticals, and believes Ipsen will turn Onivyde's fortunes around.